By identifying genetic mutations (e.g., EGFR, KRAS) and predicting tumor behavior, AI enables more precise preoperative planning and risk stratification, guiding the extent of resection, lymph node dissection, or multimodal therapy selection. This evidence concerns the gene KRAS and neoplasm.